Physician profile
Teressa J Patrick
NPI 1992786222
$9,856.70
in general payments reported to CMS, 2019-2025
36 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $879 · 2021: $1,771 · 2022: $1,895 · 2023: $2,107 · 2024: $573 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,827 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.64 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,498.09 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,899.37 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $744.71 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $739.26 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $538.35 | 2019-2025 | |
| Qol Medical, LLC | $376.05 | 2021-2024 | Sucraid, Sucraid |
| Celgene Corporation | $359.70 | 2021-2024 | Zeposia |
| Genzyme Corporation | $301.15 | 2022-2025 | |
| Gilead Sciences, INC. | $267.23 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $264.24 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $242.58 | 2020-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $186.23 | 2021-2023 | |
| Daiichi Sankyo INC. | $156.80 | 2019-2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $145.38 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $113.47 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $95.02 | 2020-2022 | |
| Braintree Laboratories, INC. | $82.96 | 2019-2022 | |
| Shionogi INC | $80.49 | 2019-2020 | |
| Organon LLC | $79.10 | 2023-2025 | Renflexis, Hadlima |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Intercept Pharmaceuticals, INC. | $68.40 | 2019-2021 | |
| Celltrion USA INC. | $67.76 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $66.02 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $64.30 | 2025 | Zenpep, Vowst |
| Romark Laboratories, Lc | $42.10 | 2019 | |
| Shire North American Group INC | $34.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.89 | 2024 | Voquezna |
| Lilly USA, LLC | $20.36 | 2023 | |
| Ardelyx, INC. | $19.85 | 2022 | |
| Fresenius Kabi USA, LLC | $16.64 | 2023 | |
| Vivus LLC | $15.80 | 2019 | |
| Novo Nordisk INC | $14.99 | 2025 | Wegovy |
| Evoke Pharma, INC. | $13.99 | 2025 | |
| Ucb, INC. | $13.86 | 2019 | |
| Capsovision, INC. | $12.78 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teressa Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.